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Subjective symptom assessment should be a fundamental
component of health-related quality of life (HRQL)
assessment in end-stage renal disease (ESRD). Unfortunately,
no symptom checklist has established reliability or validity in
ESRD. We report the validation of a modified Edmonton
Symptom Assessment System (ESAS) in 507 dialysis patients
who concurrently completed the Kidney Dialysis Quality of
Life-Short Form (KDQOL-SF) questionnaire. The ESAS
demonstrated a mean of 7.572.5 symptoms. The symptoms
reported as most severe were tiredness, well-being, appetite,
and pain. The overall symptom distress score was strongly
correlated with the KDQOL-SF subscales symptom/problem
list (r¼0.69, Po0.01), effects of kidney disease (r¼0.52,
Po0.01), and burden of kidney disease (r¼0.50, Po0.01),
as well as lower RAND-12 physical health composite (PHC)
(r¼0.54, Po0.01) and lower RAND-12 mental health
composite (MHC) (r¼0.62, Po0.001). In the multivariate
regression analysis, after controlling for potential
confounding variables including comorbidity using the
modified Charlson Comorbidity Index, the ESAS symptom
distress score remained strongly associated with the
MHC (slope¼0.8270.07, Po0.01) and PHC
(slope¼0.4870.07, Po0.01). The ESAS symptom distress
score accounted for 29% of the impairment in PHC and 39%
of the impairment in MHC. The intraclass correlation
coefficient for the total symptom distress score in a 1-week
test–retest was 0.70, Po0.01. Symptom burden is high and
adversely affects HRQL in dialysis patients. The modified
ESAS is a reliable, valid, simple, and useful method for regular
symptom assessment in this patient population.
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Health-related quality of life (HRQL) is a critical issue in the
treatment of end-stage renal disease (ESRD) and is used to
assess the effectiveness of healthcare interventions. In fact,
patient-reported HRQL is becoming as important as
morbidity and mortality in evaluating outcomes in patients
with ESRD. The relevance of HRQL is derived not only
because it is a basic aspect of health, but also because a close
relationship exists between HRQL, morbidity, and mortal-
ity.1–3
In the oncology and HIV literature, there is a clear inverse
relationship between symptoms and HRQL, leading investi-
gators to focus on decreasing symptom burden as a way to
improve patient well-being.4,5 ESRD patients are known to
have a high symptom burden6,7 yet similar work in
nephrology is limited. Recent research suggests that dialysis
patients’ perceptions of symptom burden may be more
important than objective clinical assessments in determining
HRQL.8–13 A comprehensive assessment of physical and
emotional symptom burden in dialysis patients is essential if
efforts to improve HRQL of this patient population are to be
successful. Although many instruments currently used to
evaluate the HRQL of dialysis patients have items pertaining
to symptoms, a comprehensive and psychometrically tested
questionnaire for the assessment of physical and psycholo-
gical symptoms in this population is lacking. The tools used
to evaluate symptom burden must be simple, easily under-
stood by the patient and staff, and take little time to
complete. They must also be reliable, and valid, and have
sufficient sensitivity and responsiveness. Symptom checklists
have been used in ESRD14–16 but none have established
reliability or validity. We report the validation of a modified
Edmonton Symptom Assessment System (ESAS) in a
population of dialysis patients who concurrently completed
the Kidney Dialysis Quality of Life-Short Form (KDQOL-SF)
questionnaire.17
RESULTS
Five hundred and seven of 560 eligible dialysis patients
(90.5%) completed both the ESAS and the KQOL-SF.
Patients were elderly (63.5716.0 years), mostly Caucasian
(72.6%), on hemodialysis (89.9%), and diabetic (42.4%)
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(Table 1). The majority of patients completed the surveys
themselves (73.3%): 24.5% were caregiver assisted and 2.2%
were completed by the caregiver (family member or nurse).
Table 2 summarizes the symptom burden and HRQL scores
for these patients. The ESAS demonstrated a mean of
7.572.5 symptoms, and a mean of 4.572.9 moderate or
severe symptoms. The symptoms reported as most severe
were tiredness, well-being, appetite, and pain. HRQL was also
markedly impaired. The most frequently reported symptoms
were tiredness (92.1%), decreased well-being (91.5%), poor
appetite (83.2%), and itching (77.3%) (data not shown).
As hypothesized, we observed strong correlations between
the ESAS and all the HRQL scores (Table 3). Each individual
item on the ESAS was significantly correlated with the
physical health composite (PHC) and mental health compo-
site (MHC) scores: pain most highly correlated with the PHC
(r¼0.56, Po0.01) and depressed most highly correlated
with the MHC (r¼0.57, Po0.01). The overall symptom
distress score was strongly correlated with the KDQOL-SF
subscales symptom/problem list (r¼0.69, Po0.01), effects
of kidney disease (r¼0.52, Po0.01), and burden of kidney
disease (r¼0.50, Po0.01) as well as lower PHC (r¼0.54,
Po0.01) and lower MHC (r¼0.62, Po0.001) (Figure 1).
Having a greater number of moderate or severe symptoms
was highly associated with lower PHC and MHC scores
(Figure 2). There was no correlation between biochemical
markers, including Kt/V, serum albumin, hemoglobin,
calcium, phosphorous, and any of the ESAS scores or HRQL
measures.
In the multivariate regression analysis, after controlling for
potential confounding variables including comorbidity using
diabetic status and the modified Charlson Comorbidity
Index, the ESAS symptom distress score remained strongly
Table 1 | Patient characteristics
n=507 %








Pacific Islander 18 3.6
Indian Subcontinent 16 3.2
















Peritoneal dialysis 51 10.1
Years on dialysis 3.472.8
Charlson comorbidity Index 7.172.8
DM, diabetes mellitus; ESRD, end-stage renal disease; GN, glomerulonephritis; HTN,
hypertension; PCKD, polyaptic kidney disease.
Table 2 | Symptom burden and HRQL scores
Mean7s.d. n=507 (%)
ESAS symptoms Moderate or
severe symptom
Tired 5.172.7 374 (73.8)
Well-being 4.272.5 305 (60.2)
Appetite 3.772.7 246 (48.6)
Pain 3.673.1 241 (47.7)
Itching 3.673.1 232 (45.8)
Drowsy 3.472.8 226 (44.6)
Anxious 2.972.9 196 (38.7)
Depressed 2.872.8 195 (38.5)
Shortness of breath 2.672.8 171 (33.8)
Nauseated 2.172.5 128 (25.2)
Total symptom distress score 34.1718.4
Number of symptoms 7.572.5




RAND-12 physical health composite 35.9711.2
RAND-12 mental health composite 38.9711.0
Symptom/problems 70.7716.6
Effects of kidney disease 60.8722.2
Burden of kidney disease 31.9731.6
ESAS, Edmonton Symptom Assessment System; HRQL, health-related quality of life;
KDQOL-SF, Kidney Dialysis Quality of Life-Short Form.













Pain 0.56 0.43 0.70
Tired 0.45 0.53 0.65
Well-being 0.41 0.45 0.53
Drowsy 0.35 0.44 0.71
Shortness of breath 0.35 0.35 0.61
Anxious 0.34 0.52 0.62
Depressed 0.32 0.57 0.53
Appetite 0.31 0.34 0.57
Nauseated 0.28 0.27 0.67
Itching 0.19 0.22 0.61
Total symptom distress score 0.54 0.62 0.70
aIntraclass correlation for a random sample of one-week test-retest data (n=165).
ESAS, Edmonton Symptom Assessment System; HRQL, health-related quality of life.
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associated with the MHC (slope¼0.8270.07, Po0.01)
and PHC (slope¼0.4870.07, Po0.01). Symptom burden
as described by the ESAS symptom distress score accounted
for 29% of the impairment in PHC and 39% of the
impairment in MHC in these dialysis patients.
A random sample of 165 hemodialysis patients partici-
pated in the 1-week test–retest of the ESAS. The intraclass
correlation coefficient for the total symptom distress score
was 0.70, Po0.01 (Table 3).
DISCUSSION
HRQL is intended to be a holistic concept, which includes
physical, psychological, and social domains of health. Each
domain can be expressed in different ways according to the
subjective perception of each patient, resulting in a different
assessment of HRQL. Therefore, two patients with similar
clinical and therapeutic conditions may assess HRQL
differently, because the concept is the result of the interaction
between the patient’s life conditions and the way in which
these are perceived by the patient.18 These perceptions may
be quite different than those of the clinician. It is therefore
not surprising that recent research suggests that dialysis
patients’ perceptions may be more important than objective
clinical assessments in determining HRQL.8–13 Subjective
symptom assessment, therefore, should be a fundamental
component of HRQL assessment in ESRD. Unfortunately, no
symptom checklist has established reliability or validity in
ESRD.
The most widely used HRQL instruments such as the
KDQOL and the Medical Outcomes Study 36-Item Short
form Health Survey (SF-36) do not directly assess patient
self-report of troublesome symptoms. In the formal literature
review for the Choices for Healthy Outcomes in Caring for
ESRD, only 19% of instruments included a patient self-report
of HRQL, only 13% queried symptoms, and only 8%
inquired about pain.19 Comprehensive symptom assessments
may be time consuming and difficult for patients to
complete. Because of the debilitated and symptomatic status
of this patient population, there is need for a short, simple
symptom assessment instrument that requires minimal effort
from both the patient and staff.
In this cross-sectional study, we validated a modified
version of the ESAS, a simple method for the assessment of
physical and psychological symptoms in dialysis patients.
Both overall symptom distress and the number of moderate
or severe symptoms as measured by the ESAS were strongly
correlated with all domains of HRQL. Prior studies of
symptoms in dialysis patients, although limited, support this
concept.15,20 Symptom burden has been described to account
for one-third of the impairment observed in HRQL in
dialysis patients.20 This is consistent with the findings in this
study where 39% of the mental and 29% of physical HRQL,
as measured by the MHC and PHC, respectively, was
accounted for by the ESAS overall symptom distress score.
The lack of significant association between various clinical
parameters and HRQL reinforces the relative importance
from a patient perspective of symptom burden on their
perception of HRQL. These data add to the increasing
evidence suggesting that the symptom burden of dialysis
patients is tremendous and that this burden has a significant
negative impact on patients’ HRQL. The number and severity
r = –0.54 (p < 0.01)  
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Figure 1 | Correlation between symptom burden and (a) mental
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Figure 2 | Relationship between the number of moderate or
severe symptoms and physical and mental HRQL.
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of symptoms reported by our patients is similar to that
reported by patients hospitalized in palliative care settings
with cancer.21
There are several limitations to the current study.
Participants were recruited from a single program and were
primarily Caucasian, potentially limiting the generalizability
of the results. Other patient demographics, however, are
similar to the general Canadian and US dialysis popula-
tion.22,23
This version of the ESAS is not inclusive of the entire
repertoire of symptoms experienced by this population and
therefore may under-represent the true symptom burden. It
is possible that symptoms of importance to this patient
population may have been overlooked. On the contrary, in
this study, as in our previous assessment of the ESAS in
dialysis patients,7 additional symptoms were not reported
with any significant frequency using the additional, un-
labelled visual analogue scale. Regardless, the 10 items on the
ESAS are highly associated with HRQL. We also believe that
the brevity of this scale is important if this tool is to be
clinically useful. The ESAS inquires about current trouble-
some symptoms. This time frame may result in under-
reporting of symptoms by patients.
Lastly, we used a 1-week time period to collect test–retest
data. This may be concerning if some of these symptoms are
extremely transient. We felt it was important to avoid recall
bias and to limit the effect of a non-mid-week dialysis
treatment on the results. Further, the correlation coefficients
in this study were similar to test–retest reliability data for the
ESAS in cancer patients using a similar time frame.21
Nonetheless, this scale must be further validated in studies
looking at longitudinal and predictive validity to determine
the impact of change in symptom burden on HRQL and
the usefulness of the ESAS in assessing patient long-term
outcome.
CONCLUSIONS
Symptom burden is high and adversely affects HRQL in this
patient population. The significant symptom burden and
impairment in HRQL highlights the importance of efforts to
improve these issues. Clinicians wanting to provide compre-
hensive care and improve dialysis patients’ HRQL should pay
greater attention to self-reported physical and psychological
symptoms. We conclude that this modified ESAS is a reliable,
valid, simple, and useful method for regular symptom
assessment in dialysis patients. In contrast to the use of
HRQL instruments in routine clinical practice, the resources
required for data collection, analysis, and reporting of the
ESAS are minimal. Better assessment and treatment of
patients’ symptoms would seem to have the potential to exert
a positive effect on dialysis patients’ HRQL.
MATERIALS AND METHODS
The Health Research Ethics Board of the University of Alberta
approved all study procedures. Prevalent dialysis patients in the
Northern Alberta Renal Program, a Canadian university-based renal
program were surveyed in May 2004. Participants included
peritoneal dialysis patients and in-center and satellite hemodialysis
patients from eight hemodialysis units. Patients were excluded
if they were o18 years of age, refused or were unable to complete
the questionnaires because of cognitive impairment, acute illness,
general frailty, or a language barrier. Hemodialysis patients
completed the surveys while on dialysis during a mid-week
treatment and peritoneal dialysis patients completed the surveys
while attending their regular clinic appointment. The hemodialysis
or clinic nurse assisted patients in completing the forms when
required. We administered the surveys twice, 7 days apart, to a
random subset of the hemodialysis patients using the same
procedure to obtain test–retest reliability data.
Measurement tools
The ESAS is a, simple, and widely used tool for measuring physical
and psychological symptom distress, previously validated in cancer
patients.21 The ESAS consists of nine visual analogue scales, with a
superimposed 0–10 scale for pain, activity, nausea, depression,
anxiety, drowsiness, appetite, well-being, and shortness of breath.
The scale for each symptom is anchored by the words ‘No’ and
‘Severe’ at 0 and 10, respectively. Content validity for the ESAS in
ESRD was assessed by both expert review and patient participation.
We initially reviewed the literature to determine the most common
and burdensome of symptoms for dialysis patients. We had also
previously surveyed a sample of 531 peritoneal and hemodialysis
patients, looking at the frequency of common symptoms.7 Using
this information, we added a 10th item, pruritus, to the ESAS. The
sum of the scores for all 10-symptom items was defined as the
overall symptom distress score and ranged from 0 to 100. In
addition, we provided an additional, unlabelled visual analogue
scale for patients to nominate and assess a less common symptom
that might be important for them.
We also administered the KDQOL-SFTM, Version 1.317 as a self-
report measure of HRQL. The KDQOL-SF was developed for
individuals with kidney disease and incorporates kidney-disease-
targeted items as well as a generic core. The generic core of the
KDQOL-SF was scored using the recommended methods for the
RAND-12.24 The RAND-12 measures physical and mental dimen-
sions of health and contains the same 12 items as the SF-12, taken
from the eight scales of the SF-36/RAND-36.24 Six of the 12 items
create the PHC and the remaining six items create the MHC. The
derivation of these summary scores is based on item response theory
and oblique (correlated) factor rotations.24 The RAND method of
scoring offers several theoretical advantages over the standard SF-12
scoring, which is based on principle component factor analysis with
orthogonal factor rotations.25 The RAND scoring approach better
discriminates between known groups and appears more responsive
to change.26–29
Age, sex, race, cause of ESRD, comorbidity, duration of therapy
for ESRD, Kt/V, dialysis modality, hemoglobin, calcium, phos-
phorus, parathyroid hormone, and serum albumin concentrations
were collected. We determined the modified Charlson Comorbidity
Index as a measure of comorbid conditions30 as this index has been
shown to adjust for the potential confounding effect of comorbidity
in studies of HRQL.31
Statistical analysis
SPSS 13.0 for windows was used to perform statistical analysis.
A Po0.05 was considered for statistical significance. Patient
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characteristics were described as frequencies and percentages or as
mean7s.d. Similar descriptive statistics were obtained for each of
the 10 symptoms on the ESAS as well as the total symptom distress
score and the number of moderate or severe symptoms where
moderate is defined as 4–6 and severe 7–10 on the ESAS 0–10 Likert
scale. Descriptive statistics were also obtained for the PHC, MHC,
and the KDQOL-SF summary scores: symptom/problem list, effects
of kidney disease, and burden of kidney disease.
Construct validity was tested by the general hypothesis that
increased symptom burden would be associated with impairments
in HRQL. We therefore expected ESAS scores would be negatively
correlated with the KDQOL symptom/problem list, effects of kidney
disease, burden of kidney disease, and RAND-12 PHC and MHC
scores. Furthermore, we anticipated the magnitude of these
correlations to be strong (i.e., Spearman 40.5), with similar
constructs (e.g., pain and PHC or depressed and MHC) having the
strongest relationships. We anticipated that the overall symptom
distress score would be most strongly correlated with the KDQOL-
SF symptom/problem list. We also obtained correlations between
ESAS overall symptom distress score and modified Charlson
Comorbidity Index, Kt/V, hemoglobin, serum albumin, calcium,
phosphorous. We hypothesized that these objective clinical para-
meters would have weaker correlations with self-reported symptom
distress.
In univariate analysis, the ESAS symptom distress score, MHC,
and PHC were compared by using t-test for dichotomous variables
(gender, Caucasian vs others, diabetic status and modality of
dialysis), and correlation and linear regression analyses were
conducted with continuous variables (age, years on dialysis,
modified Charlson Comorbidity Index). Multivariate regression
analysis was performed using stepwise selection by increasing
Po0.25 in the initial model and Po0.05 in the final parsimonious
model.
Test–retest validity was assessed by calculating the intraclass
correlation coefficients between the 10 individual ESAS items and
the overall symptom distress score for the baseline and 1-week
follow-up measurements.
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